Your browser doesn't support javascript.
loading
Flow cytometry diagnosis in myelodysplastic syndrome: Current practice in Latin America and comparison with other regions of the world.
Grille, S; Iastrebner, M; Lorand-Metze, I; van der Velden, V H J; Ikoma, M R V; Vidal-Senmache, G; Colado, E; Rabelo-Carrasco, L J; Blanco, A; Huamán-Garaicoa, F; O'Connor, J E; Cao Pochintesta, C; Jensen, E; Bacal, N S; Díaz, L; Lens, D.
Afiliación
  • Grille S; Laboratorio de Citometria y Biologia Molecular, Departamento Basico de Medicina, Hospital de Clínicas, Facultad de Medicina, Universidad de la Republica, Montevideo, Uruguay; Catedra de Hematologia, Hospital de Clinicas, Universidad de la Republica, Montevideo, Uruguay.
  • Iastrebner M; Servicio de Hematologia, Sanatorio "Sagrado Corazón", Buenos Aires, Argentina.
  • Lorand-Metze I; Hematology - Hemotherapy Center, University of Campinas, Campinas, São Paulo, Brazil.
  • van der Velden VHJ; Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Dutch Cytometry Society, the Netherlands.
  • Ikoma MRV; Laboratory of Cytometry, Hospital Amaral Carvalho, Jaú, São Paulo, Brazil.
  • Vidal-Senmache G; Hospital Edgardo Rebagliati Martins, Lima, Peru.
  • Colado E; Hematology and Laboratory Medicine Department and Instituto Universitario de Oncología del Principado de Asturias, Central University Hospital of Asturias, Oviedo, Spain.
  • Rabelo-Carrasco LJ; Hospital de Especialidades. Centro Médico Nacional Siglo XXI- IMSS, Ciudad de México, Mexico.
  • Blanco A; Flow Cytometry Core Technologies, UCD Conway Institute, University College Dublin, Dublin, Ireland.
  • Huamán-Garaicoa F; Universidad Catolica de Santiago de Guayaquil, Instituto Oncologico Nacional SOLCA, Ecuador.
  • O'Connor JE; Laboratory of Cytomics, Joint Research Unit CIPF-UVEG, Department of Biochemistry and Molecular Biology, University of Valencia, Valencia, Spain.
  • Cao Pochintesta C; Clinica Universidad de Los Andes y Laboratorio Citometría de Redsalud, Santiago de Chile, Chile.
  • Jensen E; Hospital Nacional de Niños, San José, Costa Rica.
  • Bacal NS; Clinical Pathology Laboratory, Division of Hematology and Flow Cytometry, Hospital Israelita Albert Einstein, São Paulo, Brazil.
  • Díaz L; Catedra de Hematologia, Hospital de Clinicas, Universidad de la Republica, Montevideo, Uruguay.
  • Lens D; Laboratorio de Citometria y Biologia Molecular, Departamento Basico de Medicina, Hospital de Clínicas, Facultad de Medicina, Universidad de la Republica, Montevideo, Uruguay. Electronic address: daniela.lens@gmail.com.
Leuk Res ; 79: 69-74, 2019 04.
Article en En | MEDLINE | ID: mdl-30773246
BACKGROUND: Flow cytometry (FC) is a valuable tool for the diagnosis of myelodysplastic syndromes (MDS). We present results of a survey carried out to evaluate FC current practice for MDS diagnosis in Latin America (LA), focusing on markers used and characteristics of the clinical diagnostic report. Compliance to IMDSflow recommendations was also evaluated. These practices were then compared with those used in other countries. METHODS: An online survey was sent through the Grupo Latino-Americano de Mielodisplasia to LA cytometrists and other international scientific societies. RESULTS: 91 responses from 15 LA countries were received. The median of the number of markers used was 20 ± 4.5, but only 8.1% of participants adopted the complete panel proposed by the International/European LeukemiaNet Working Group (IMDSflow). We received 140 eligible answers from regions other than LA (66 Europe, 59 USA-Canada, 8 Oceania, 6 Asia and 1 Africa). LA utilized more markers for MDS diagnosis than USA/Canada (p = 0.006), but similar to Europe. The use of MDS scoring systems differed among regions: 10.3% in LA, 0% USA/Canada and 25.7% Europe reported the "Ogata score". Finally, 52.0% of all participants included a general interpretation statement in the final report about the consistency of the FC results with MDS diagnosis, with no statistical differences between regions. CONCLUSIONS: This survey shows a low compliance with the IMDSflow recommendations and a scarce use of the scoring systems proposed in the literature. However, the number of surface markers used is high. We will work to develop a FC consensus for MDS diagnosis adapted to the clinical practice requirements in LA.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Síndromes Mielodisplásicos / Pautas de la Práctica en Medicina / Citometría de Flujo Tipo de estudio: Diagnostic_studies / Guideline / Prognostic_studies Límite: Humans País/Región como asunto: Africa / America do norte / Asia / Europa / Oceania Idioma: En Revista: Leuk Res Año: 2019 Tipo del documento: Article País de afiliación: Uruguay Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Síndromes Mielodisplásicos / Pautas de la Práctica en Medicina / Citometría de Flujo Tipo de estudio: Diagnostic_studies / Guideline / Prognostic_studies Límite: Humans País/Región como asunto: Africa / America do norte / Asia / Europa / Oceania Idioma: En Revista: Leuk Res Año: 2019 Tipo del documento: Article País de afiliación: Uruguay Pais de publicación: Reino Unido